MR-linac: role of artificial intelligence and automation
- PMID: 39843783
- PMCID: PMC11839841
- DOI: 10.1007/s00066-024-02358-9
MR-linac: role of artificial intelligence and automation
Abstract
The integration of artificial intelligence (AI) into radiotherapy has advanced significantly during the past 5 years, especially in terms of automating key processes like organ at risk delineation and treatment planning. These innovations have enhanced consistency, accuracy, and efficiency in clinical practice. Magnetic resonance (MR)-guided linear accelerators (MR-linacs) have greatly improved treatment accuracy and real-time plan adaptation, particularly for tumors near radiosensitive organs. Despite these improvements, MR-guided radiotherapy (MRgRT) remains labor intensive and time consuming, highlighting the need for AI to streamline workflows and support rapid decision-making. Synthetic CTs from MR images and automated contouring and treatment planning will reduce manual processes, thus optimizing treatment times and expanding access to MR-linac technology. AI-driven quality assurance will ensure patient safety by predicting machine errors and validating treatment delivery. Advances in intrafractional motion management will increase the accuracy of treatment, and the integration of imaging biomarkers for outcome prediction and early toxicity assessment will enable more precise and effective treatment strategies.
Keywords: Artificial intelligence; Automation; Imaging biomarkers; Intrafractional motion management; MR-guided radiation therapy.
© 2025. The Author(s).
Conflict of interest statement
Conflict of interest: The University Hospital Zurich has research and teaching agreements with Siemens Healthineers. The University Hospital Zurich had research and teaching agreements with ViewRay in the past. S. Corradini received research funds and speaker honoraria from Brainlab, Elekta, and ViewRay. J. Hörner-Rieber received speaker fees from Pfizer Inc., Astra Zeneca, Sanofi, and ViewRay Inc.; travel reimbursement from Varian Medical Systems; and research grants from IntraOP Medical and Varian Medical Systems outside the submitted work. S. Tanadini-Lang received travel reimbursement from Varian Medical Systems. S. Psoroulas and A. Paunoiu declare that they have no competing interests.
Figures
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
